The move should be helpful as the DNA-sequencing specialist develops diagnostic tests that require his former agency's approval.
News & Analysis: Illumina
Illumina’s share of the sequencing market, new collaboration agreement with Roche, and growth in the clinical oncology business position it for long-term revenue growth.
A confluence of worries over genetic privacy and fear of an economic downturn have investors worried over Illumina's prospects.
There was one surprise with the genomic sequencing leader's latest update.
ILMN earnings call for the period ending December 31, 2019.
These are pretty much slam dunks for the company's upcoming quarterly update.
The two companies aim to make significant advances in cancer research and make genomics accessible to more patients.
Will the gene sequencing company announce news that boosts its shares at the J.P. Morgan Healthcare Conference?
DNA sequencing giant Illumina dropped a deal that would have brought it complementary technology. Going it alone might be a better bet for the company and investors.
Which of these two genetics stocks is more likely to continue rising in value?